Your browser doesn't support javascript.
loading
BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme.
Thorne, Heather; Devereux, Lisa; Li, Jason; Alsop, Kathryn; Christie, Liz; van Geelen, Courtney T; Burdett, Nikki; Pishas, Kathleen I; Woodford, Noel; Leditschke, Jodie; Izzath, Mohamed H M A; Strachan, Kate; Young, Gregory; Jaravaza, Rufaro D; Madadin, Mohammed S; Archer, Melanie; Glengarry, Joanna; Iles, Linda; Rathnaweera, Ajith; Hampson, Clare; Almazrooei, Khamis; Burke, Michael; Bandara, Pradeep; Ranson, David; Saeedi, Essa; McNally, Orla; Mileshkin, Linda; Hamilton, Anne; Ananda, Sumitra; Au-Yeung, George; Antill, Yoland; Sandhu, Shahneen; Savas, Peter; Francis, Prudence A; Luen, Stephen; Loi, Sherene; Jennens, Ross; Scott, Clare; Moodie, Kate; Cummings, Margaret; Reid, Andrew; McCart Reed, Amy; Bowtell, David; Lakhani, Sunil R; Fox, Stephen.
Afiliação
  • Thorne H; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
  • Devereux L; Research Department, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Li J; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
  • Alsop K; Research Department, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Christie L; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
  • van Geelen CT; Research Department, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Burdett N; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
  • Pishas KI; Research Department, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Woodford N; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
  • Leditschke J; Research Department, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Izzath MHMA; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
  • Strachan K; Research Department, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Young G; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
  • Jaravaza RD; Research Department, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Madadin MS; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
  • Archer M; Research Department, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Glengarry J; The Victorian Institute of Forensic Medicine, Southbank, Australia.
  • Iles L; Department of Forensic Medicine, Monash University, Clayton, Australia.
  • Rathnaweera A; The Victorian Institute of Forensic Medicine, Southbank, Australia.
  • Hampson C; The Victorian Institute of Forensic Medicine, Southbank, Australia.
  • Almazrooei K; The Victorian Institute of Forensic Medicine, Southbank, Australia.
  • Burke M; The Victorian Institute of Forensic Medicine, Southbank, Australia.
  • Bandara P; The Victorian Institute of Forensic Medicine, Southbank, Australia.
  • Ranson D; National Health Laboratory Service, Tygerberg Hospital, Cape Town, South Africa.
  • Saeedi E; Division of Anatomical Pathology, Stellenbosch University, Stellenbosch, South Africa.
  • McNally O; The Victorian Institute of Forensic Medicine, Southbank, Australia.
  • Mileshkin L; Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
  • Hamilton A; The Victorian Institute of Forensic Medicine, Southbank, Australia.
  • Ananda S; The Victorian Institute of Forensic Medicine, Southbank, Australia.
  • Au-Yeung G; The Victorian Institute of Forensic Medicine, Southbank, Australia.
  • Antill Y; The Victorian Institute of Forensic Medicine, Southbank, Australia.
  • Sandhu S; The Victorian Institute of Forensic Medicine, Southbank, Australia.
  • Savas P; The Victorian Institute of Forensic Medicine, Southbank, Australia.
  • Francis PA; The Victorian Institute of Forensic Medicine, Southbank, Australia.
  • Luen S; The Victorian Institute of Forensic Medicine, Southbank, Australia.
  • Loi S; Base Hospital Dambulla, Dambulla, Sri Lanka.
  • Jennens R; Base Hospital Puttlam, Puttlam, Sri Lanka.
  • Scott C; The Victorian Institute of Forensic Medicine, Southbank, Australia.
  • Moodie K; The Victorian Institute of Forensic Medicine, Southbank, Australia.
  • Cummings M; Abu Dhabi Police, Abu Dhabi, United Arab Emirates.
  • Reid A; The Royal Women's Hospital, Parkville, Australia.
  • McCart Reed A; The University of Melbourne, Parkville, Australia.
  • Bowtell D; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
  • Lakhani SR; Research Department, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Fox S; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Histopathology ; 83(1): 91-103, 2023 07.
Article em En | MEDLINE | ID: mdl-36999648
ABSTRACT

AIM:

To catalogue and compare the pattern of metastatic disease in germline BRCA1/2 pathogenic mutation carriers and non-carriers with breast, ovarian and prostate cancer from a rapid autopsy programme. METHODS AND

RESULTS:

The number of metastases in the major body systems and the proportion of participants with metastases were documented in 50 participants (19 germline mutation carriers). Analysis was conducted on the participants' pattern of disease for the different cancers and mutation subgroups. The four commonly affected organ systems were the digestive (liver only) (82%), respiratory (76%), gastrointestinal (65%) and reticuloendothelial (42%). There were significant differences in the pattern of metastatic breast cancer in BRCA1/2 germline carriers compared with non-carriers. Breast cancer carriers had significantly fewer organ systems involved (median n = 3, range = 1-3) compared with non-carriers (median n = 9, range = 1-7) (P = 0.03). BRCA1/2 carriers with ovarian carcinomas had significantly more organ systems with metastatic carcinoma (median n = 10, range = 3-8) than non-carriers (median n = 5, range = 3-5) (P < 0.001). There were no significant differences in the number of involved systems in BRCA2 carriers compared with non-carriers with prostate cancer (P = 1.0). There was an absence of locoregional disease (6.5%) compared with distant disease (93.5%) among the three cancer subtypes (P < 0.001). The majority of metastatic deposits (97%) collected during the autopsy were identified by recent diagnostic imaging.

CONCLUSION:

Even though a major limitation of this study is that our numbers are small, especially in the breast cancer carrier group, the metastatic patterns of breast and ovarian cancers may be impacted by BRCA1/2 carrier status, suggesting that tumours derived from patients with these mutations use different mechanisms of dissemination. The findings may focus clinical diagnostic imaging for monitoring metastases where whole-body imaging resources are scant.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias da Próstata / Neoplasias da Mama Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Histopathology Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias da Próstata / Neoplasias da Mama Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Histopathology Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália